Dendritic cell vaccination against ovarian cancer-tipping the Treg/T H17 balance to therapeutic advantage?

Expert Opinion on Biological Therapy

Volumn 11, Issue 4, 2011, Pages 441-445

  Cannon, Martin J ^a   Goyne, Hannah ^a   Stone, Pamela J B ^a   Chiriva Internati, Maurizio ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

dendritic cells; ovarian cancer; p38 MAPK; regulatory T cells; TH17 T cells

Indexed keywords

DENDRITIC CELL VACCINE; INTERLEUKIN 10; INTERLEUKIN 17; MITOGEN ACTIVATED PROTEIN KINASE P38;

ACTIVE IMMUNIZATION; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CYTOKINE RESPONSE; ENZYME INHIBITION; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; OVARY CANCER; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH17 CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; DENDRITIC CELLS; FEMALE; HUMANS; INTERLEUKIN-17; LYMPHOCYTES, TUMOR-INFILTRATING; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 79952612330     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.554812     Document Type: Review

References (38)

1. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9 (Pubitemid 39273735)
2. Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11:8326-31 (Pubitemid 41746944)
3. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-43 (Pubitemid 43011261)
4. Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance ofTh17 cells in the human tumor environments. Blood 2009;114:1141-9
5. Kryczek I, Wei S, Zou L, et al. Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007;178:6730-3 (Pubitemid 46847396)
6. Bettelli E, Oukka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8:345-50 (Pubitemid 46745409)
7. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nature Immunol 2007;8:942-9 (Pubitemid 47300008)
8. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nature Immunol 2007;8:950-7 (Pubitemid 47300009)
9. Liu H, Rohowsky-Kochan C. Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol 2008;180:7948-57
10. Munn DH. Th17 cells in ovarian cancer. Blood 2009;114:1134-5
11. Tartour E, Fossiez F, Joyeux I, et al. Interleukin 17,a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999;59:3698-704 (Pubitemid 29381875)
12. Numasaki M, Watanabe M, Suzuki T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005;175:6177-89 (Pubitemid 41508106)
13. Nam J-S, Terabe M, Kang M-J, et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008;68:3915-23
14. Zhu X, Mulcahy LA, Mohammed RAA, et al. Il-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness ofbreast cancer cell lines. Breast Cancer Res 2008;10:R95
15. Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009;206:1457-64
16. Murugaiyan G, Saha B. Protumor vs antitumor functions ofIL-17. J Immunol 2009;183:4169-75
17. Martin-Orozco N, Muranski P, Chung Y, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009;31:787-98
18. Gnerlich JL, Mitchem JB, Weir JS, et al. Induction ofTh17 cells in the tumor microenvironment improves overall survival in a murine model of pancreatic cancer. J Immunol 2010;185:4063-71
19. Kryczek I, Wei S, Szeliga W, et al. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009;114:357-9
20. Derhovanessian E, Adams V, Hahnel K, et al. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with preclinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 2009;125:1372-9
21. Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112:362-73
22. Jackson AM, Mulcahy LA, Zhu XW, et al. Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation. Int J Cancer 2008;123:623-32 (Pubitemid 351898421)
23. Xie J, Qian J, Yang J, et al. Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells. Exp Hematol 2005;33:564-72 (Pubitemid 40592173)
24. Wang S, Hong S, Yang J, et al. Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 2006;108:4071-7 (Pubitemid 44913277)
25. Zhao F, Falk C, Osen W, et al. Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in Ret transgenic mice spontaneously developing melanoma. Clin Cancer Res 2009;15:4382-90
26. Jarnicki AG, Conroy H, Brereton CF, et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008;180:3797-806
27. Brereton CF, Sutton CE, Lalor SJ, et al. Inhibition of ERK MAPK suppresses IL-23-and IL-1-driven IL-17 production and attenuates autoimmune disease. J Immunol 2009;183:1715-23
28. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nature Med 2002;8:793-800
29. Curiel TJ, Wei S, Dong H, et al. Blockade ofB7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Med 2003;9:562-7 (Pubitemid 36597102)
30. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007;104:3360-5 (Pubitemid 46364164)
31. Sharma MD, Hou D-Y, Liu Y, et al. Indoleamine 2,3 dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009;113:6102-11
32. Chung DJ, Rossi M, Romano E, et al. Indoleamine 2,3-dioxygenase- expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009;11:555-63
33. Okamoto A, Nikaido T, Ochiai K, et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005;11:6030-9 (Pubitemid 41170335)
34. Inaba T, Ino K, Kajiyama H, et al. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 2009;115:185-92
35. Buckanovich RJ, Facciabene A, Kim S, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008;14:28-36
36. Kandalaft LE, Facciabene A, Buckanovich RJ, et al. Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res 2009;15:4521-8
37. Kandalaft LE, Singh N, Liao JB, et al. The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecol Oncol 2010;116:222-33
38. Zhang L, Dermawan K, Jin M, et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol 2008;129:219-29